Extruded Oral Dosage Forms with Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing solid oral dosage forms with controlled active ingredient release face challenges such as variability in release rates, mechanical instability, and difficulty in controlling granule size and porosity, leading to inconsistent therapeutic effects.
Innovation Solution
A process involving the joint processing of a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone in an extruder at temperatures between 50° and 200° C under pressure, resulting in a low-porosity extruded mixture with enhanced mechanical stability and reproducible release profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional granulation techniques or direct tableting are used with erodable substances or gel formers, then the active ingredient release can be controlled, but the release varies greatly from tablet to tablet and from batch to batch, and mechanical stability is insufficient
Solution Approach 1:
The patent changes the processing parameters by using extrusion at controlled temperatures (50-200°C) and pressures (2-25 MPa) to process the preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone with active ingredients. This parameter change transforms the processing method from conventional granulation or direct tableting to extrusion, achieving both consistent release and improved mechanical stability
Solution Approach 2:
The patent uses a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone as a composite material system. This composite material combines the properties of both polymers to create a matrix that provides both controlled release and mechanical stability, resolving the contradiction between release consistency and mechanical strength
2Ease of manufacture
If polyvinyl acetate is softened by heating to 40-130°C for granulation, then the powder particles cohere to give granule particles, but the granule size and porosity are difficult to control, making the process more difficult to control
Solution Approach 1:
The patent extends the temperature range to 50-200°C and applies pressure (2-25 MPa) during extrusion, changing the processing parameters from simple heating to controlled extrusion. This allows precise control over granule size and porosity while maintaining ease of manufacture through a standardized extrusion process
Solution Approach 2:
The extrusion process provides feedback control through measurable parameters such as pressure (2-25 MPa), temperature (50-200°C), and extrusion rate, allowing precise adjustment of granule size and porosity. The porosity is controlled to be less than 10% by volume, with preferred ranges of less than 5% and particularly preferably less than 1%
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a controlled, sustained release of active ingredients with improved mechanical stability and reduced variability, ensuring consistent therapeutic effects and increased resistance to crushing.
Implementation Method 1
the mixture of components a) and b) takes place by joint processing of a) and b) in an extruder at temperatures between 50° and 200° C
Implementation Method 2
The extrusion takes place under a pressure of from 2 to 25 MPa
Data Source
AI summary
A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture ofa) at least one active ingredient, andb) a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone,wherein the mixture is obtained by joint processing of components a) and b) in an extruder at temperatures between 50° and 200° C.